
It is unclear whether systolic blood pressure (BP) and pulse pressure (PP), either clinic or ambulatory, differ in their ability to predict heart failure (HF) in elderly hypertensive patients. To evaluate the influence of clinic and ambulatory systolic BP and PP on HF risk in elderly treated hypertensive subjects. In this retrospective study, we assessed 1314 individuals (aged ≥ 65 years) undergoing clinic and ambulatory BP measurement. Association of BP parameters with HF was investigated by univariable and multivariable Cox regression analyses. Differences between competing models were assessed by receiver operating characteristic curve (ROC) analysis, Akaike’s Information Criterion (AIC) and Schwarz Bayesian Information Criterion (BIC). During the follow-up (7.0 ± 4.0 years), 126 HF events occurred. After adjustment for covariates, clinic systolic BP and PP were not significantly associated with HF risk, whereas daytime systolic BP, daytime PP, nighttime systolic BP and nighttime PP were, showing a hazard ratio (95
Elevated blood pressure (BP) is the leading cause of cardiovascular disease and a major contributor to mortality, affecting almost one third of the adult population worldwide. Despite strong scientific evidence, guidelines and multiple therapeutic options, many patients remain undertreated or uncontrolled, largely due to poor medication adherence and medical inertia. Complexity of multi-pill regimens contributes significantly to non-adherence, whereas single-pill combinations (SPCs) improve adherence and persistence, accelerate BP control, and promote better long-term outcomes than multiple combinations. Appropriate selection of SPC in individual hypertensive patients may be a difficult though very important task for physicians. Thus, development of tools that may facilitate use of SPC in clinical practice is desirable. Among renin–angiotensin system blockers, olmesartan (OM) has demonstrated sustained efficacy, favourable tolerability, both as monotherapy and in SPCs with amlodipine and/or hydrochlorothiazide, which are available in multiple dosages. The present OM-based platform builds on earlier frameworks and incorporates guidelines’ updates complemented by a systematic review of available literature. This “3.0” proposal expands patient categorization to include comorbidities or complications often overlooked in clinical practice guidelines, providing a practical, evidence-based approach to support individualized hypertension management complementing guideline recommendations. The Olmesartan-Based Treatment Platform 3.0 provides a practical framework for the individualized management of hypertension. Following phenotypic characterization, treatment is tailored according to cardiovascular risk, hypertension-mediated organ damage, comorbidities, and out-of-office blood pressure profile, supporting evidence-based selection and intensification of olmesartan-based therapies to achieve optimal blood pressure control and cardiovascular protection.
Renal involvement is increasingly recognized in Systemic Sclerosis (SSc) and Sjögren’s Disease (SjD). However, the association between hypertension and renal function decline in these conditions remains poorly understood. to compare renal function changes over time in patients with SSc and SjD; identify factors associated with clinically relevant renal function decline; and to evaluate whether the association between hypertension and renal function differs between the two diseases. We retrospectively analyzed patients with SSc and SjD, followed for up to 3 years. Renal function was assessed using estimated glomerular filtration rate (eGFR). Clinically relevant renal decline was defined as a reduction in eGFR ≥10 ml/min Multivariable logistic regression identified factors associated with renal function decline, including the interaction between diagnosis and hypertension. A total of 238 patients were included (114 with SSc and 124 with SjD), with a median age of 55 years (IQR 45–65) in SSc and 57 years (IQR 48–66) in SjD. At baseline, SSc patients showed higher eGFR compared to SjD, but experienced a greater decline over time (median −6 vs −2.1 ml/min, p < 0.05). Overall, 33.8
Increased arterial stiffness is a sign of vascular damage; therefore, assessing it is crucial for evaluating cardiovascular risk. Arterial stiffness parameters such as pulse wave velocity (PWV) and augmentation index (at heart rate 75 bpm, AIX@75) were shown to correlate directly with blood pressure (BP). Since these parameters may consequently be altered in patients with white coat effect (WCE), this study examined differences in office and 24h measurements of these parameters across various BP phenotypes. In this multicenter cross-sectional study, conducted between 2018 and 2023 at three nephrology clinics, office and 24h BP measurements and pulse wave analysis (PWA) of 208 patients were examined. 189 patients were included; 48 were diagnosed with controlled hypertension (HTN), 63 with uncontrolled HTN, 22 with a masked HTN phenotype, 30 with WCE, of whom 11 had white coat HTN (WCH) and 19 had white coat uncontrolled HTN (WCUH), and 26 had normal BP. By definition, patients with WCE had significantly higher office peripheral and aortic BP than the respective 24h values (p<0.0001 each). Their AIX@75 was significantly higher on office (32.7±11.4